12/2/2020 6:15:19 AM
Mesoblast: FDA Grants Fast Track Designation For Remestemcel-L For ARDS Due To COVID-19
11/11/2020 6:07:24 AM
Mesoblast: Second Interim Analysis Of Outcomes Results In Recommendation To Continue Remestemcel-L Phase 3 Trial
10/13/2020 6:03:46 AM
Mesoblast Says Phase 3 Trial Of Remestemcel-L Surpassed 50% Enrollment
9/2/2020 6:10:13 AM
Mesoblast Secures Ethics Approval To Treat COVID-19 Patients In Australia